Long‑term effectiveness of baricitinib and other b/tsDMARDs in patients with rheumatoid arthritis with early low disease activity or remission: 2‑year data from the RA‑BE‑REAL study
Rheumatol Ther 2025 10.1007/s40744-025-00815-0 Epub ahead of print
This real-world analysis from the RA-BE-REAL study evaluated early achievement of remission or LDA at 3 months and long-term outcomes at 24 months in adults with RA starting baricitinib or other b/tsDMARDs. Patients who achieved remission/LDA at 3 months experienced greater improvements in pain, physical function, and quality of life compared with patients who did not.